https://www.selleckchem.com/products/cytidine.html
Alternative endpoints, such as lack of progression and improvement in physical functioning or quality of life, may be suitable for clinical trials in patients with highly morbid manifestations. Finally, new approaches for objective response assessment and exploration of novel trial designs for small populations are required.Recent studies have renewed the debate on infectious etiology in late-onset Alzheimer's disease. Bocharova et al. reported that abundant expression of human beta amyloid (Aβ) in the mouse brain (5XFAD animals) faile
Like
Comment
Share
